Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care.
BACKGROUND
HIV-infected injection drug users consistently report poor antiretroviral therapy use and little contact with health care providers. It has been suggested that the clinical setting where patients are seen affects the use of highly active antiretroviral therapy.


OBJECTIVE
The purpose of this study was to determine whether ease of access to medical care affects self-report of taking antiretroviral therapy, particularly among female injection drug users.


METHODS
The study is a cross-sectional analysis from a prospective cohort study of HIV-infected women.


METHODS
Women were enrolled at four sites in the United States: Detroit, Michigan, and Providence, Rhode Island, where on-site HIV care and treatment were offered, and Baltimore, Maryland, and the Bronx, New York, where all participants were referred elsewhere for HIV care and treatment.


METHODS
Patients were HIV-infected women with no AIDS diagnosis or women who were at risk for HIV infection either through self-reported injection drug use since 1985 or through sexual contact.


METHODS
The study measured self-reported use of antiretroviral therapy (ART) alone or combined with Pneumocystis carinii (PCP) prophylaxis in the previous 6 months.


RESULTS
In multivariate analysis including type of study site (on-site compared with referral care) and injection drug use, any self-reported ART use associated with low CD4 cell count category, older age, and race. However, at on-site care centers, women were equally likely to report ART use regardless of current, former, or no injection drug use, whereas at referral sites only women identified as sexual contacts were more likely to report any ART use, independent of all other variables.


CONCLUSIONS
Easy access to medical care has an important impact on HIV-infected women receiving ART, particularly those who are active injection drug users.
Rompalo
A M
AM
Johns Hopkins Schools of Medicine and Public Health, Baltimore, Maryland 21287-0003, USA. arompalo@jhmi.edu
Shah
N
N
Mayer
K
K
Schuman
P
P
Klein
R S
RS
Smith
D K
DK
Vlahov
D
D
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008875:Middle Aged; D010349:Patient Compliance; D012017:Referral and Consultation; D015819:Substance Abuse, Intravenous / Q000523:psychology*
D019380:Anti-HIV Agents